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ABSTRACT
Introduction Acute rhinosinusitis (ARS) is a prime reason 
for doctor visits and among the conditions with highest 
antibiotic overprescribing rates in adults. To reduce 
inappropriate prescribing, we aim to predict the absolute 
benefit of antibiotic treatment for individual adult patients 
with ARS by applying multivariable risk prediction methods 
to individual patient data (IPD) of multiple randomised 
placebo- controlled trials.
Methods and analysis This is an update and re- analysis 
of a 2008 IPD meta- analysis on antibiotics for adults with 
clinically diagnosed ARS. First, the reference list of the 2018 
Cochrane review on antibiotics for ARS will be reviewed 
for relevant studies published since 2008. Next, the 
systematic searches of CENTRAL, MEDLINE and Embase of 
the Cochrane review will be updated to 1 September 2020. 
Methodological quality of eligible studies will be assessed 
using the Cochrane Risk of Bias 2 tool. The primary 
outcome is cure at 8–15 days. Regression- based methods 
will be used to model the risk of being cured based on 
relevant predictors and treatment, while accounting for 
clustering. Such model allows for risk predictions as a 
function of treatment and individual patient characteristics 
and hence gives insight into individualised absolute benefit. 
Candidate predictors will be based on literature, clinical 
reasoning and availability. Calibration and discrimination 
will be evaluated to assess model performance. Resampling 
techniques will be used to assess internal validation. In 
addition, internal–external cross- validation procedures 
will be used to inform on between- study differences and 
estimate out- of- sample model performance. Secondarily, 
we will study possible heterogeneity of treatment effect as 
a function of outcome risk.
Ethics and dissemination In this study, no identifiable 
patient data will be used. As such, the Medical Research 
Involving Humans Subject Act (WMO) does not apply and 
official ethical approval is not required. Results will be 
submitted for publication in international peer- reviewed 
journals.
PROSPERO registration number CRD42020220108.
INTRODUCTION
Acute rhinosinusitis (ARS) is a prime reason 
for primary care visits in adults.1–3 At present, 
accurate diagnosis of ARS is challenging and 
general practitioners have to rely on a specific 
signs and symptoms.4 Although viral of origin 
and self- limiting in the majority of cases,5–7 
ARS is among the conditions with highest 
antibiotic overprescription rates in adults.1 8 
The lack of evidence to support management 
decisions in adults with ARS might explain 
the apparent overuse of diagnostic tools and 
medications such as antibiotics, intranasal 
corticosteroids, anthistamines and mucol-
ytics in everyday practice.9 Tailored guidance 
Strengths and limitations of this study
 ► By applying multivariable risk prediction model-
ling approaches to individual patient data (IPD) of 
multiple randomised placebo- controlled trials, this 
study aims to identify relevant differential absolute 
treatment effects of antibiotics in adults with acute 
rhinosinusitis in primary care.
 ► The large number of participants and events avail-
able in the IPD set allow us to evaluate up to 25 
parameters in the model.
 ► Due to the retrospective nature, it is possible that 
some potentially helpful predictors cannot be in-
cluded in our analyses due to unavailability in the 
majority of studies.
 ► Since an externally developed risk model is not 
available, we will develop a model using an inter-
nal–external cross validation procedure.
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based on identification of patients that are most likely 
to benefit from antibiotics has the potential to substan-
tially reduce inappropriate prescribing in this common 
condition.10
A previous individual patient data (IPD) meta- analysis of 
randomised controlled trials (RCTs) comparing antibiotics 
with placebo in adults with clinically diagnosed ARS aimed 
to provide such guidance.7 This IPD meta- analysis combined 
data from 2547 participants in nine trials and investigated 
whether common signs and symptoms such as duration of 
symptoms, body temperature, pain on bending and purulent 
nasal discharge modified antibiotic effectiveness. By applying 
conventional (one- variable- at- a- time) subgroup analysis,11–13 
no single sign or symptoms could be identified to predict 
antibiotic benefit.7 However, evidence is accumulating that 
underlying clinical heterogeneity is likely under- represented 
and potential important differences in treatment effects 
may be obscured when taking only single variables into 
account.11–13 Prediction modelling approaches which allow 
for simultaneous analysis of multiple baseline variables that 
may influence treatment effect have the potential to over-
come these problems and can be used to predict differential 
absolute treatment effects, the most useful scale for clinical 
decision making.13–16 These approaches are considered most 
valuable when (1) an overall treatment effect exists, (2) treat-
ment may lead to substantial harm/burden, (3) substantial 
heterogeneity in the trial population is anticipated (broad 
case mix), (4) multiple RCTs are available and appropriate 
for pooling in IPD meta- analysis and (5) covariates in the 
model are routinely available in everyday practice.15 16 With 
antibiotics for clinically diagnosed ARS in adults meeting 
all these criteria, we aim to predict the benefit of antibiotic 
treatment for individual patients by applying multivariable 
risk prediction modelling approaches to IPD of multiple 
placebo- controlled trials in this field. This may ultimately 
improve patient care by more judicious prescription of anti-
biotics in adults with ARS and thereby curb antimicrobial 
resistance.
METHODS
The protocol is reported according to the Preferred 
Reporting Items for Systematic Review and Meta- Analysis 
protocols (PRISMA- P) statement.17 The IPD meta- 
analysis will follow the recommendations provided in the 
Predictive Approaches to Treatment effect Heterogeneity 
(PATH) statement15 and the guidance on the use of IPD 
meta- analyses of diagnostic and prognostic modelling 
studies18 and reported according to the PRISMA- IPD 
statement.19
Patient and public involvement
Patients were not involved in development of the protocol.
Identification of relevant studies: a systematic review
A systematic review will be performed to identify and 
select any relevant studies published since the 2008 IPD 
meta- analysis.7
Study eligibility criteria
All RCTs comparing antibiotics with placebo in patients 
with clinically diagnosed ARS will be eligible. Study 
participants must be ≥16 years of age suspected by their 
physician of having uncomplicated ARS based on clin-
ical signs and symptoms and presenting in a primary 
healthcare setting (ie, patients who are not referred by a 
physician because of the current ARS episode, or patients 
presenting through self- referral in ambulatory care or 
an emergency department). No language or publication 
date restrictions will be applied. Studies involving chil-
dren (<16 years), referred patients, hospitalised patients 
as well as those involving highly specialised populations 
(eg, those with immunodeficiency, odontogenic sinusitis 
or malignancy) will be excluded.
Search strategy
First, the reference list of the 2018 Cochrane review on 
antibiotics for ARS in adults6 will be reviewed for any rele-
vant studies published since the 2008 IPD meta- analysis.7 
Next, the systematic electronic searches of the Cochrane 
review will be updated from 18 January 2018 (date of 
last search) to 1 September 2020 to increase the yield of 
potentially relevant trials (online supplemental file 1). In 
addition, reference lists of all eligible studies as well as 
those from relevant systematic reviews will be screened 
for any further potential studies. Finally, contributing 
review authors will be asked if they are aware of any addi-
tional (published or unpublished) studies.
Study selection
One review author (RPV) will review the reference list 
of the 2018 Cochrane review6 for any additional trials, 
where relevant full texts will be retrieved. Next, two 
review authors (RPV, JH) will independently screen titles 
and abstracts of the unique records obtained from the 
electronic database searches to assess their potential rele-
vance for reviewing the full text. The same review authors 
will independently review the full text of all potentially 
eligible articles against the predefined inclusion and 
exclusion criteria. Any disagreements will be resolved by 
discussion and if necessary, a third review author (JBR) 
will be consulted.
Data extraction and management
Corresponding authors of eligible trials published since 
the 2008 IPD meta- analysis7 will be contacted via an 
email. They will be invited to collaborate and share their 
de- identified, complete IPD of their original study in 
their preferred format. A data sharing agreement will be 
provided. Study data will be considered unavailable when 
none of the authors respond to multiple contact attempts 
or if study authors indicate that the requested data are 
not available or cannot be shared.
On retrieval, the IPD of individual studies will be 
reviewed against published data by comparing key vari-
ables (eg, number of participants, descriptive analysis of 
demographic characteristics). We will ask collaborators 
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for clarification in case important discrepancies are iden-
tified. The amount of missing data within each study will 
be assessed and discussed with collaborators to reduce 
missing data as much as possible.
SPSS V.25 and R (R Foundation for Statistical 
Computing, Vienna, Austria) will be used for the statis-
tical analyses. An aggregated database will be created 
containing a trial ID variable (to identify participants 
from the same study), patient demographics and charac-
teristics including clinical signs and symptoms, treatment 
allocation (antibiotics or placebo) and outcome measure 
of interest (whether or not proportion of patients were 
clinically cured at days 8–157). The aggregated database 
will have a multilevel structure (with individual trials as 
levels or clusters). Missing data will be studied and appro-
priate methods for handling them, such as multiple impu-
tation, will be considered.20–22
Quality assessment of included studies
Two review authors (RPV, JH) will independently assess 
the methodological quality of the included studies using 
the Cochrane Risk of Bias 2 tool.23 This tool allows to judge 
the risk of bias for the primary outcome of interest as ‘low’, 
‘high’ or ‘some’ concerns for following five domains: (1) 
bias arising from the randomisation process, (2) bias due 
to deviations from the intended interventions, (3) bias 
due to missing outcome data, (4) bias in measurement 
of outcome, (5) bias in selection of the reported results. 
Any disagreements will be resolved by discussion and if 
necessary, a third review author (JBR) will be consulted. 
If information regarding study quality is unclear or undis-
closed, individual study authors will be contacted.
Data synthesis
Descriptive analysis and evidence synthesis
For all studies contributing IPD, study and participants’ 
characteristics will be provided. We will review the char-
acteristics of eligible studies that did not contribute IPD 
to investigate whether there is any evidence of selection 
(availability) bias.
IPD meta-analysis using outcome risk prediction
Outcome of interest
The main outcome of interest will be whether or not 
patients are cured at 8–15 days as per the definition applied 
in the 2008 IPD meta- analysis, that is, cure as defined in 
an individual trial or by agreement with the primary inves-
tigator in advance of the analysis with patients receiving 
an antibiotic in addition to or as replacement for the 
randomly assigned treatment regarded as not cured.7
Candidate predictors
Candidate predictors will be based on clinical reasoning, 
knowledge from existing literature and availability in the 
IPD set.
There is currently no externally developed prediction 
model available and insufficient evidence on poten-
tially useful predictors of prolonged illness duration in 
adults with ARS.4 7 The 2020 European Position Paper 
on Rhinosinusitis and Nasal Polyps states that the pres-
ence of three or more of the following five symptoms 
increases the likelihood of acute bacterial rhinosinusitis 
(ABRS): (1) the presence of fever (>38°C), (2) double 
sickening, (3) unilateral disease, (4) severe pain, (5) 
raised C reactive protein (CRP) or erythrocyte sedimen-
tation rate (ESR) values.4 However, further research into 
combinations of signs and symptoms predictive of ABRS 
in primary care is warranted.4 24
A recent systematic review found limited evidence that 
overall clinical impression, cacosmia and pain in teeth are 
the best predictors of ABRS.25 Using data from a single 
diagnostic accuracy study,26 preceding upper respira-
tory tract infection (URTI), preceding ARS, unilateral 
maxillary pain, pain in teeth, purulent nasal discharge 
and CRP >15 mg/L were predictive of positive bacterial 
culture of fluid from antral puncture.27 Of these variables, 
only raised CRP or ESR rates have been proven useful to 
predict antibiotic benefit in adult patients with clinically 
diagnosed ARS in one trial.28
Based on these considerations and clinical reasoning, 
potential candidate predictors include: (1) preceding 
URTI, (2) preceding ARS, (3) age, (4) duration of symp-
toms, (5) symptom severity, (6) maxillary pain (any, unilat-
eral, bilateral), (7) pain in teeth, (8) pain on bending, 
(9) anosmia, (10) cacosmia, (11) double sickening, (12) 
overall clinical impression, (13) fever (>38°C), (14) 
purulent nasal discharge on examination, (15) purulent 
discharge in pharynx on examination, (16) CRP and 
(17) ESR. Continuous variables (age, CRP, ESR) will be 
kept continuous and the functional relationship with the 
outcome will be assessed through restricted cubic splines.
Sample size considerations
Recent methodological work has provided guidance with 
respect to sample size considerations for developing a 
clinical prediction model.29 The key rationale is to link 
desired risk prediction accuracy to sample size. We antici-
pate IPD availability for 2541 participants and an outcome 
proportion of 0.4.7 Due to the clustered nature of the data, 
the effective sample size will be smaller than 2541, but 
the available guidance does not yet extend to this setting. 
Conservatively estimating the effective sample size to be 
1250, this allows for evaluation of up to 25 parameters in 
the model for a desired 0.05 accuracy in terms of mean 
absolute prediction error. Based on an anticipated Cox- 
Snell R2 of 0.175, this is also expected to keep shrinkage 
below 10% and the expected Cox- Snell R2 within 5%.
Model development and evaluation
The aggregated IPD set will be used to inform which 
predictors can be included in our model. Reasons for 
dropping variables will be based on non- availability in 
>50% of the studies and critical between- study hetero-
geneity in definition of a variable. The final decision to 
drop a variable based on this criterion will be based on 
consensus within research team. Next, remaining predic-
tors will be included in a mixed effect logistic regression 
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model30 together with treatment.15 16 Currently, there is 
no strong evidence in favour of clear pre- specification of 
treatment–covariate interactions in this setting. We will 
therefore include treatment–covariate interaction terms 
for variables indicative of ABRS according to the litera-
ture and perform a single pooled test for their combined 
significance. Based on this test, we either keep or remove 
the entire group of treatment–covariate interactions from 
the model. The overall ability of the model to discrimi-
nate between patients with and without clinical cure at 
8–15 days will be quantified using the c- statistic. Calibra-
tion of the model will be assessed visually with calibration 
plots.
Since an initial prediction model commonly shows a too 
optimistic discrimination and calibration, that is, over-
fitting, we will use bootstrapping for internal validation 
and to guide possible adjustment for overfitting. Large 
unexplained between- study heterogeneity in predictive 
accuracy of the resulting model will be explored and 
discussed. Ultimately this may lead to adjustment of the 
model by dropping the variables that contribute most to 
the observed heterogeneity. Lastly, we will perform an 
internal–external cross validation procedure31 to estimate 
model performance outside the context of the acquired 
IPD. In this procedure, each study will be left out once 
for evaluation purposes while the model is fitted on the 
remaining studies. The final model will be based on the 
entire pooled dataset. The resulting absolute risk predic-
tions under both treatments (antibiotics and placebo) 
and the predicted absolute treatment effects will be 
displayed graphically.
Secondary analysis
As a secondary analysis, we will study possible treatment 
effect heterogeneity as a function of outcome risk.15 16 
The underlying rationale is that the absolute benefit 
of antibiotic treatment may continue to increase as the 
risk of an unfavourable outcome increases, while this 
is not reflected by a common OR. To this end, we will 
first develop a model for outcome risk and subsequently 
evaluate a mixed logistic model of outcome risk, treat-
ment, and a possibly non- linear interaction between 
the two. Methods for evaluation and presentation of 
the results of the latter model are conform the primary 
analysis.
It is worth noting that a model including all possible 
treatment interactions, as opposed to the risk score 
summary used here, would be both more likely to 
capture the true underlying mechanism (since it allows 
relative treatment effect to vary as a function of each 
predictor) and overfit the data (for the same reason). 
Due to this risk of overfitting, even given the anticipated 
set of IPD, we chose to evaluate differential treatment 
effect as a function of a limited number of high poten-
tial treatment interactions in the primary analysis, and 
as a function of an overall risk score in this secondary 
analysis.
Ethics and dissemination
There will be no identifiable patient data in any of the 
datasets. As such, the Medical Research Involving Humans 
Subject Act (WMO) does not apply to this study. The 
Medical Research Ethics Committee Utrecht, the Neth-
erlands, reviewed the study protocol (protocol 20-719/C) 
and concluded that an official approval was not required.
All principal investigators will provide written confirma-
tion that all participants included in the original studies 
had given full written informed consent. Data will be 
stored within a secured folder of the data management 
department of the Julius Center for Health Sciences and 
Primary Care, University Medical Center Utrecht. On 
completion of the study, data will be stored for the at least 
15 years at a central drive of the data management depart-
ment of the Julius Center and will be made available for 
the use by third parties on request and approval of the 
research team.
Research findings will be published in international 
peer- reviewed journals and will be presented at national 
and international scientific conferences.
Review registration and anticipated end date of study
The review has been registered in PROSPERO; 
CRD42020220108. The anticipated end date of data 
collection is March 2021 and the anticipated end date of 
the study is October 2021.
DISCUSSION
High- quality data indicate that antibiotics on average have 
only limited beneficial effects in adults with clinically diag-
nosed ARS.6 7 Nevertheless, antibiotic prescribing rates 
remain at a high level in this common condition; anti-
biotics are prescribed in around 50% of patients in the 
Netherlands and up to 90% of patients in the UK and the 
USA.1–3 This routine practice exposes individual patients 
to common side effects32 and both the individual as well 
as the population to emerging antimicrobial resistance.33 
One of the reasons for the persistant habit to prescribe 
antibiotics to patients with ARS might be attributed to 
clinicians’ gut feeling that there is a subgroup of patients 
that do benefit from antibiotics.10 There is some evidence 
to substantiate this impression; antibiotics seems to have 
larger effects in those with a radiologically confirmed 
diagnosis, in particular those with fluid level or total 
opacification in any sinus on CT.6 Unfortunately, current 
attemps to identify these subgroups of patients including 
a previous IPD meta- analysis were not successful.7
In this update and re- analysis of the IPD meta- analysis,8 
we aim to predict the benefit of antibiotic treatment for 
individual patients by applying multivariable risk predic-
tion methods.13–15 Missing data, in particular those missing 
for all individuals in one or more trials, pose a particular 
challenge in this project. Despite using multiple impu-
tation methods to address missing data, it is likely that 
some potentially helpful predictors cannot be included 
in our IPD meta- analysis due to non- availability in >50% 
copyright.
 on A













pen: first published as 10.1136/bm




5Venekamp RP, et al. BMJ Open 2021;11:e047186. doi:10.1136/bmjopen-2020-047186
Open access
of the studies. Nonetheless, the large number of partic-
ipants available in the IPD set will allow us to include a 
substantial number of candidate predictors in our model, 
thereby providing a unique opportunity to identify poten-
tial heterogeneity of antibiotic effectiveness in adults with 
clinically diagnosed ARS.
As per recent guidance, we propose to incorporate only 
a limited number of multiplicative treatment- by- coviarte 
interaction terms into the model.15 16 Further method-
ological research will be needed to identify methods 
that can effectively explore a wider spectrum of treat-
ment–covariate interactions, while minimising the risk of 
modelling spurious associations also known as overfitting. 
Further remaining uncertainties and questions when 
it comes to best practices for PATH include: (1) what is 
the optimal way to examine multiplicative treatment- by- 
continuous covariate interactions, (2) how will results 
vary between different approaches for covariate selection 
and shrinkage, (3) how to best examine and express the 
impact of heterogeneity of treatment effects between 
individual studies, and do (4) other statistical approaches 
such as latent- class analysis and (5) more recent data- 
analytical approaches such as artificial intelligence have 
any benefit in modelling heterogeneity of treatment 
effect.
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Supplemental File 1. Search strategy 
 
 
We will search the following databases from 18 January 2018 to 1 September 2020 using the database specific 
search strategies specified below: (1) the Cochrane Central Register of Controlled Trials (CENTRAL; 2020, Issue 
8) in the Cochrane Library, (2) MEDLINE via Ovid (from January 2018 to September 2020), and (3) Embase via 
Elsevier (from January 2018 to September 2020). 
 
Database Search strategy 
CENTRAL 
and MEDLINE 






7 ((suppurative or purulent) adj2 (nasal discharge or rhinitis or rhinorrhoea or rhinorrhoea)).tw. 
8 or/1‐7 
9 exp Anti‐Bacterial Agents/ 
10 antibacterial*.tw. 
11 antibiotic*.tw. 





































49 (miocamycin* or miokamycin*).tw,nm. 
50 moxifloxacin*.tw,nm. 
51 norfloxacin.tw,nm. 
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62 tetracyclines/ or tetracycline/ 
63 tetracycline*.tw,nm. 
64 Trimethoprim‐Sulfamethoxazole Combination/ 
65 trimethoprim‐sulfamethoxazole combination.tw,nm. 
66 cotrimoxazole*.tw,nm. 
67 or/9‐66 
68 8 and 67 
Embase #21 #12 AND #20 
#20 #15 NOT #19 
#19 #16 NOT #18 
#18 #16 AND #17 
#17 'human'/de 
#16 'animal'/de OR 'nonhuman'/de OR 'animal experiment'/de 
#15 #13 OR #14 
#14 crossover*:ab,ti OR 'cross‐over':ab,ti OR 'cross over':ab,ti OR placebo*:ab,ti OR (doubl* 
NEXT/1 blind*):ab,ti OR allocat*:ab,ti OR random*:ab,ti OR trial:ti 
#13 'randomized controlled trial'/exp OR 'single blind procedure'/exp OR 'double blind 
procedure'/exp OR 'crossover procedure'/exp 
#12 #6 AND #11 
#11 #7 OR #8 OR #9 OR #10 
#10 amoxicillin:ab,ti OR ampicillin*:ab,ti OR azithromycin:ab,ti OR cefaclor:ab,ti OR 
cefadroxil:ab,ti OR cefatrizine:ab,ti OR cefuroxim*:ab,ti OR cephalexin*:ab,ti OR 
cephalosporin*:ab,ti OR ciprofloxacin*:ab,ti OR clarithromycin*:ab,ti OR clindamycin:ab,ti OR 
doxycyclin*:ab,ti OR erythromycin*:ab,ti OR fluoroquinolone*:ab,ti OR levofloxacin*:ab,ti OR 
lincomycin*:ab,ti OR macrolide*:ab,ti OR minocyclin*:ab,ti OR miocamycin*:ab,ti OR 
miokamycin*:ab,ti OR moxifloxacin*:ab,ti OR norfloxacin*:ab,ti OR ofloxacin*:ab,ti OR 
penicillin*:ab,ti OR quinolone*:ab,ti OR spiramycin*:ab,ti OR telithromycin*:ab,ti OR 
tetracyclin*:ab,ti OR trimethoprim*:ab,ti OR cotrimoxazol*:ab,ti 
#9 'amoxicillin'/de OR 'ampicillin'/de OR 'azithromycin'/de OR 'cefaclor'/de OR 'cefadroxil'/de OR 
'cefuroxime'/de OR 'cefalexin'/de OR 'cephalosporin'/de OR 'ciprofloxacin'/de OR 
'clarithromycin'/de OR 'clindamycin'/de OR 'doxycycline'/de OR 'erythromycin'/de OR 
'lincomycin'/de OR 'macrolide'/de OR 'quinolone derivative'/de OR 'minocycline'/de OR 
'miokamycin'/exp OR 'norfloxacin'/de OR 'ofloxacin'/de OR 'penicillin derivative'/de OR 
'spiramycin'/de OR 'tetracycline derivative'/de OR 'cotrimoxazole'/de 
#8 antibiotic*:ab,ti 
#7 'antibiotic agent'/exp 
#6 #1 OR #2 OR #3 OR #4 OR #5 
#5 ((suppurative OR purulent) NEAR/2 ('nasal discharge' OR rhinitis OR rhinorrhea OR 
rhinorrhoea)):ab,ti 
#4 rhinit*:ab,ti OR rhinosinusit*:ab,ti OR nasosinusit*:ab,ti 
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